The management of mucosal leishmaniasis in immunocompromised patients is not standardized and limited data are available on the use of miltefosine for treatment and secondary prophylaxis. We describe a case of mucosal leishmaniasis in an HIV-coinfected patient treated with miltefosine due to a severe allergic reaction to liposomal amphotericin B.
Use of miltefosine in a patient with mucosal leishmaniasis and HIV-coinfection: a challenge in long-term management / Zanelli, G., Rossetti, B., Gagliardini, R., Paglicci, L., Tordini, G., Miracco, C., Aversa, S., Zammarchi, L., Di Muccio, T., Gramiccia, M., Montagnani, F.. - In: LE INFEZIONI IN MEDICINA. - ISSN 1124-9390. - ELETTRONICO. - 27:(2019), pp. 452-455.
Use of miltefosine in a patient with mucosal leishmaniasis and HIV-coinfection: a challenge in long-term management
Zanelli, Giacomo
;Paglicci, Lorenzo;Miracco, Clelia;Zammarchi, Lorenzo;
2019
Abstract
The management of mucosal leishmaniasis in immunocompromised patients is not standardized and limited data are available on the use of miltefosine for treatment and secondary prophylaxis. We describe a case of mucosal leishmaniasis in an HIV-coinfected patient treated with miltefosine due to a severe allergic reaction to liposomal amphotericin B.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
